Prostate-Specific Membrane Antigen
VIDEO: Androgen receptor pathway inhibitors ‘have transformed’ prostate cancer management
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
VIDEO: Upfront use of PARP, ARPI combination may offer greater survival benefit
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
VIDEO: New targets sought for advanced prostate cancer treatment
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
VIDEO: PSMA PET imaging 'single most important advance' in advanced prostate cancer
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
Data confirm safety of active surveillance among patients with low-risk prostate cancer
Prostate cancer is a complex cancer, with patients who present differently with various clinical staging and criteria; thus, follow-up care after treatment also differs among this patient population.
For some men, delaying salvage therapy after prostate cancer surgery boosts mortality risk
Delaying salvage radiation therapy after radical prostatectomy for men with just one high-risk factor for prostate cancer recurrence may significantly increase risk for all-cause mortality, a study in Journal of Clinical Oncology showed.
FDA approves Pluvicto for certain men with advanced prostate cancer
The FDA approved lutetium Lu 177 vipivotide tetraxetan for treatment of certain men with advanced prostate cancer.
VIDEO: Good safety data from Phase III VISION trial of Lu-PSMA-617
In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses the Phase 3 VISION trial.
FDA grants priority review to targeted radioligand therapy for advanced prostate cancer
The FDA granted priority review to 177Lu-PSMA-617 for treatment of certain men with advanced prostate cancer.
FDA grants breakthrough designation to radioligand therapy for advanced prostate cancer
The FDA granted breakthrough therapy designation to 177Lu-PSMA-617 for treatment of metastatic castration-resistant prostate cancer, according to the agent’s manufacturer.